Adding peptide therapy to your clinic: plan before you spend
Clinics that do not offer peptide therapies today are asking whether a new service line could add a real revenue stream. The answer depends on fit, verification and your own numbers, in that order. This page is a planning sequence, not clinical training, legal clearance or permission to treat patients.
1. Test fit first
Tally existing-patient inquiries for two weeks. Aggregate counts only, never patient records.
Name the licensed clinician who would independently own clinical decisions. Unfilled means pause.
Estimate staff hours per week the line would actually get.
2. Separate the roles
The clinic owns staffing, workflow, contracting and truthful advertising.
The licensed clinician owns clinical decisions within scope, independently.
Counsel verifies state licensure, supervision and structure for your exact facts.
A pharmacy or supplier is verified per product and per state, not from a catalog page.
3. Keep product categories distinct
Approved prescription drugs follow their FDA approval and labeling.
Compounded medications have their own federal and state conditions, which change with supply status.
Research-use materials are not a patient-care route. A "not for human use" label is a boundary, not a marketing workaround.
4. Run your own economics
Contribution per visit = your price minus your itemized variable cost.
Break-even visits = fixed setup cost divided by contribution.
Test a worse case: contribution 20 percent lower, fixed costs 20 percent higher. A line that only works in the best case does not work.
Then build a conditional roadmap
Sequence the work as gated stages: fit, verification, economics, operations build, then a go or no-go decision by a named owner. Write the stop conditions before spending. A pause with a named gap is a successful planning outcome, not a failure.
No course, consultant, supplier catalog or disclaimer grants clinical eligibility or clears a state. Qualified people verify each open question, with a source and a date, before any offering is announced.